Nuvation Bio NUVB License — Deferred Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
well as double-digit tiered royalties up to the high-teens as a percentage of future net sales in the Territory. Following the upfront payment, the Company will receive the first milestone payment of €25.0 million (approximately USD $30.0 million) from this transaction upon achievement of EU regulatory approval (conditional or full) of taletrectinib. In January 2026, upon receipt of the upfront payment, the Company recognized approximately $58.7 million in license revenue.
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's license — deferred revenue?
- Nuvation Bio (NUVB) reported license — deferred revenue of $58.7M in Q1 2026.
- What does license — deferred revenue mean?
- This metric represents the deferred revenue or performance obligations arising from licensing contracts where consideration has been received but the associated performance obligations have not yet been satisfied. It serves as a measure of future revenue that is expected to be recognized as the company fulfills its contractual commitments. This liability provides insight into the long-term service or development obligations tied to existing partnership agreements.
Ask your AI about Nuvation Bio's license — deferred revenue.
Connect your AI assistant and compare segments, right in your chat.
